Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective
Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer tre...
Gespeichert in:
| Veröffentlicht in: | Indian journal of cancer 2024-04, Vol.61 (2), p.204-214 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 214 |
|---|---|
| container_issue | 2 |
| container_start_page | 204 |
| container_title | Indian journal of cancer |
| container_volume | 61 |
| creator | Rathod, Reena J Sukumaran, Reghu K Kedia, Neelam Kumar, Jeevan Nair, Reena Chandy, Mammen Gandikota, Lakshmikanth Radhakrishnan, Vivek Sulekha |
| description | Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients. Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario. We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India. |
| doi_str_mv | 10.4103/ijc.ijc_433_21 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_3134048691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A815153283</galeid><sourcerecordid>A815153283</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-b1e162027254e957294b7eeaebfce10a506f3b58539f04ddbb7d0ccac63fa6f83</originalsourceid><addsrcrecordid>eNp9kt2L1DAUxYMo7rj66qMEBN865rNtfBsGPxYWBFnBt5AmNzsZ2rQm6YL_vRlcdYVBQki4_M65cDgIvaRkKyjhb8PRbuvVgnPN6CO0oUr1jeg68RhtCKGqkUR9u0DPcj4SwjgT_VN0wRWVrBXdBo37Q5ggBYt3sYRbiPgLWFjKnPBNY2Ec8WAyOHz6rqNJuBwgmSVAxr4y1kQL6V0V4xBLmt1qS5gjNtHhq-iCiXiBlBeo4zt4jp54M2Z4cf9eoq8f3t_sPzXXnz9e7XfXjeUdK81AgbaMsI5JAUp2TImhAzAweAuUGElazwfZS648Ec4NQ-eItca23JvW9_wSvf7lu6T5-wq56OO8plhXak65IKJvFf0_RankgrcPvG7NCDpEP5dk7BSy1bueyoqxnleqOUPVOGtY4xzBhzr-h9-e4etxMAV7VvDmgeAAZiyHPI_rKe181tmmOecEXi8pTCb90JToU2X0qS5_K1MFr-5jWIcJ3B_8d0f4T1jau2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3111534368</pqid></control><display><type>article</type><title>Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective</title><source>MEDLINE</source><source>Medknow Open Access Medical Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Bioline International</source><creator>Rathod, Reena J ; Sukumaran, Reghu K ; Kedia, Neelam ; Kumar, Jeevan ; Nair, Reena ; Chandy, Mammen ; Gandikota, Lakshmikanth ; Radhakrishnan, Vivek Sulekha</creator><creatorcontrib>Rathod, Reena J ; Sukumaran, Reghu K ; Kedia, Neelam ; Kumar, Jeevan ; Nair, Reena ; Chandy, Mammen ; Gandikota, Lakshmikanth ; Radhakrishnan, Vivek Sulekha</creatorcontrib><description>Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients. Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario. We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India.</description><identifier>ISSN: 0019-509X</identifier><identifier>EISSN: 1998-4774</identifier><identifier>DOI: 10.4103/ijc.ijc_433_21</identifier><identifier>PMID: 39152647</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Antigens ; Cancer ; Cell- and Tissue-Based Therapy - methods ; Health aspects ; Humans ; Immunotherapy, Adoptive - methods ; India ; Neoplasms - immunology ; Neoplasms - therapy ; Oncology, Experimental ; Receptors, Chimeric Antigen - immunology ; T cells ; T-Lymphocytes - immunology</subject><ispartof>Indian journal of cancer, 2024-04, Vol.61 (2), p.204-214</ispartof><rights>Copyright © 2024 Copyright: © 2024 Indian Journal of Cancer.</rights><rights>COPYRIGHT 2024 Medknow Publications and Media Pvt. Ltd.</rights><rights>2024. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c372t-b1e162027254e957294b7eeaebfce10a506f3b58539f04ddbb7d0ccac63fa6f83</cites><orcidid>0000-0001-9484-5669</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27913,27914</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39152647$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rathod, Reena J</creatorcontrib><creatorcontrib>Sukumaran, Reghu K</creatorcontrib><creatorcontrib>Kedia, Neelam</creatorcontrib><creatorcontrib>Kumar, Jeevan</creatorcontrib><creatorcontrib>Nair, Reena</creatorcontrib><creatorcontrib>Chandy, Mammen</creatorcontrib><creatorcontrib>Gandikota, Lakshmikanth</creatorcontrib><creatorcontrib>Radhakrishnan, Vivek Sulekha</creatorcontrib><title>Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective</title><title>Indian journal of cancer</title><addtitle>Indian J Cancer</addtitle><description>Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients. Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario. We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India.</description><subject>Antigens</subject><subject>Cancer</subject><subject>Cell- and Tissue-Based Therapy - methods</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>India</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Oncology, Experimental</subject><subject>Receptors, Chimeric Antigen - immunology</subject><subject>T cells</subject><subject>T-Lymphocytes - immunology</subject><issn>0019-509X</issn><issn>1998-4774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kt2L1DAUxYMo7rj66qMEBN865rNtfBsGPxYWBFnBt5AmNzsZ2rQm6YL_vRlcdYVBQki4_M65cDgIvaRkKyjhb8PRbuvVgnPN6CO0oUr1jeg68RhtCKGqkUR9u0DPcj4SwjgT_VN0wRWVrBXdBo37Q5ggBYt3sYRbiPgLWFjKnPBNY2Ec8WAyOHz6rqNJuBwgmSVAxr4y1kQL6V0V4xBLmt1qS5gjNtHhq-iCiXiBlBeo4zt4jp54M2Z4cf9eoq8f3t_sPzXXnz9e7XfXjeUdK81AgbaMsI5JAUp2TImhAzAweAuUGElazwfZS648Ec4NQ-eItca23JvW9_wSvf7lu6T5-wq56OO8plhXak65IKJvFf0_RankgrcPvG7NCDpEP5dk7BSy1bueyoqxnleqOUPVOGtY4xzBhzr-h9-e4etxMAV7VvDmgeAAZiyHPI_rKe181tmmOecEXi8pTCb90JToU2X0qS5_K1MFr-5jWIcJ3B_8d0f4T1jau2w</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Rathod, Reena J</creator><creator>Sukumaran, Reghu K</creator><creator>Kedia, Neelam</creator><creator>Kumar, Jeevan</creator><creator>Nair, Reena</creator><creator>Chandy, Mammen</creator><creator>Gandikota, Lakshmikanth</creator><creator>Radhakrishnan, Vivek Sulekha</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0001-9484-5669</orcidid></search><sort><creationdate>20240401</creationdate><title>Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective</title><author>Rathod, Reena J ; Sukumaran, Reghu K ; Kedia, Neelam ; Kumar, Jeevan ; Nair, Reena ; Chandy, Mammen ; Gandikota, Lakshmikanth ; Radhakrishnan, Vivek Sulekha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-b1e162027254e957294b7eeaebfce10a506f3b58539f04ddbb7d0ccac63fa6f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antigens</topic><topic>Cancer</topic><topic>Cell- and Tissue-Based Therapy - methods</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>India</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Oncology, Experimental</topic><topic>Receptors, Chimeric Antigen - immunology</topic><topic>T cells</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rathod, Reena J</creatorcontrib><creatorcontrib>Sukumaran, Reghu K</creatorcontrib><creatorcontrib>Kedia, Neelam</creatorcontrib><creatorcontrib>Kumar, Jeevan</creatorcontrib><creatorcontrib>Nair, Reena</creatorcontrib><creatorcontrib>Chandy, Mammen</creatorcontrib><creatorcontrib>Gandikota, Lakshmikanth</creatorcontrib><creatorcontrib>Radhakrishnan, Vivek Sulekha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Indian journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rathod, Reena J</au><au>Sukumaran, Reghu K</au><au>Kedia, Neelam</au><au>Kumar, Jeevan</au><au>Nair, Reena</au><au>Chandy, Mammen</au><au>Gandikota, Lakshmikanth</au><au>Radhakrishnan, Vivek Sulekha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective</atitle><jtitle>Indian journal of cancer</jtitle><addtitle>Indian J Cancer</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>61</volume><issue>2</issue><spage>204</spage><epage>214</epage><pages>204-214</pages><issn>0019-509X</issn><eissn>1998-4774</eissn><abstract>Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients. Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario. We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>39152647</pmid><doi>10.4103/ijc.ijc_433_21</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-9484-5669</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0019-509X |
| ispartof | Indian journal of cancer, 2024-04, Vol.61 (2), p.204-214 |
| issn | 0019-509X 1998-4774 |
| language | eng |
| recordid | cdi_proquest_journals_3134048691 |
| source | MEDLINE; Medknow Open Access Medical Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Bioline International |
| subjects | Antigens Cancer Cell- and Tissue-Based Therapy - methods Health aspects Humans Immunotherapy, Adoptive - methods India Neoplasms - immunology Neoplasms - therapy Oncology, Experimental Receptors, Chimeric Antigen - immunology T cells T-Lymphocytes - immunology |
| title | Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T08%3A35%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chimeric%20Antigen%20Receptor%20T-cell%20based%20cellular%20therapies%20for%20cancer:%20An%20introduction%20and%20Indian%20perspective&rft.jtitle=Indian%20journal%20of%20cancer&rft.au=Rathod,%20Reena%20J&rft.date=2024-04-01&rft.volume=61&rft.issue=2&rft.spage=204&rft.epage=214&rft.pages=204-214&rft.issn=0019-509X&rft.eissn=1998-4774&rft_id=info:doi/10.4103/ijc.ijc_433_21&rft_dat=%3Cgale_proqu%3EA815153283%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3111534368&rft_id=info:pmid/39152647&rft_galeid=A815153283&rfr_iscdi=true |